​

Celldex Therapeutics (CLDX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CLDX Stock Forecast

Celldex Therapeutics stock forecast is as follows: an average price target of $62.00 (represents a 146.62% upside from CLDX’s last price of $25.14) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.

CLDX Price Target

The average price target for Celldex Therapeutics (CLDX) is $62.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $80.00 to $44.00. This represents a potential 146.62% upside from CLDX's last price of $25.14.

CLDX Analyst Ratings

Buy

According to 8 Wall Street analysts, Celldex Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CLDX stock is 0 'Strong Buy' (0.00%), 5 'Buy' (62.50%), 3 'Hold' (37.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Celldex Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 29, 2024Joseph PantginisH.C. Wainwright$80.00$27.11195.04%218.22%
Sep 25, 2024Derek ArchilaWells Fargo$44.00$36.0222.15%75.02%
Jun 17, 2024Alex ThompsonStifel Nicolaus$58.00$34.9166.14%130.71%
Nov 10, 2023Derek ArchilaWells Fargo$27.00$25.784.73%7.40%
Nov 11, 2022Guggenheim$63.00$39.8957.93%150.60%

The latest Celldex Therapeutics stock forecast, released on Oct 29, 2024 by Joseph Pantginis from H.C. Wainwright, set a price target of $80.00, which represents a 195.04% increase from the stock price at the time of the forecast ($27.11), and a 218.22% increase from CLDX last price ($25.14).

Celldex Therapeutics Price Target by Period

1M3M12M
# Anlaysts-23
Avg Price Target-$62.00$60.67
Last Closing Price$25.14$25.14$25.14
Upside/Downside-100.00%146.62%141.33%

In the current month, the average price target of Celldex Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Celldex Therapeutics's last price of $25.14. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 29, 2024H.C. WainwrightBuyBuyHold
Oct 28, 2024Cowen & Co.BuyBuyHold
Oct 28, 2024Wolfe ResearchBuyBuyHold
Oct 28, 2024Wells FargoUnderperformUnderperformHold
Oct 28, 2024GuggenheimBuyBuyHold
Oct 07, 2024CitigroupBuyInitialise
Sep 30, 2024Goldman SachsNeutralInitialise
Sep 27, 2024Leerink PartnersMarket PerformDowngrade
Sep 26, 2024Wolfe ResearchBuyPeer PerformDowngrade
Sep 25, 2024GuggenheimBuyBuyHold
Sep 25, 2024Wells FargoUnderperformOverweightUpgrade
Sep 25, 2024Wells FargoUnderperformUnderperformHold
Sep 25, 2024Wolfe ResearchBuyBuyHold
Sep 09, 2024Wells FargoBuyBuyHold
Sep 09, 2024H.C. WainwrightUnderperformUnderperformHold
Aug 12, 2024H.C. WainwrightBuyBuyHold
Aug 12, 2024Wells FargoEqual-WeightEqual-WeightHold
Jul 30, 2024Cowen & Co.BuyBuyHold
Jul 16, 2024Cantor FitzgeraldUnderperformUnderperformHold
Jul 16, 2024H.C. WainwrightBuyBuyHold
Jun 10, 2024Wolfe ResearchOutperformInitialise
Jun 03, 2024H.C. WainwrightBuyBuyHold
May 07, 2024H.C. WainwrightBuyBuyHold
May 07, 2024GuggenheimUnderperformUnderperformHold
Dec 20, 2023Cantor FitzgeraldUnderperformUnderperformHold
Dec 20, 2023Wells FargoBuyBuyHold
Nov 11, 2022GuggenheimBuyBuyHold
Apr 25, 2022Zacks Investment ResearchHoldUpgrade

Celldex Therapeutics's last stock rating was published by H.C. Wainwright on Oct 29, 2024. The company gave CLDX a "Buy" rating, the same as its previous rate.

Celldex Therapeutics Financial Forecast

Celldex Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
Revenue--------$4.13M$1.52M$268.00K$967.00K$1.61M$407.00K$163.00K$174.00K$334.00K$153.00K$3.48M$685.00K$3.79M$668.00K$236.00K$2.73M$887.00K$546.00K$715.00K$1.43M$4.07M$1.53M
Avg Forecast$650.00K$433.33K$433.33K$433.33K$1.02M$835.56K$854.29K$809.00K$1.44M$583.33K$528.00K$410.00K$264.00K$360.00K$400.00K$560.00K$1.04M$1.22M$643.33K$965.00K$600.00K$395.00K$800.00K$990.00K$815.00K$1.26M$1.26M$1.26M$978.74K$1.56M
High Forecast$650.00K$433.33K$433.33K$433.33K$1.74M$835.56K$854.43K$809.00K$1.80M$583.50K$528.00K$410.00K$264.00K$360.00K$400.00K$560.00K$1.04M$1.22M$643.33K$965.00K$600.00K$395.00K$800.00K$990.00K$815.00K$1.26M$1.26M$1.26M$1.17M$1.87M
Low Forecast$650.00K$433.33K$433.33K$433.33K$655.91K$835.56K$854.14K$809.00K$1.07M$583.17K$528.00K$410.00K$264.00K$360.00K$400.00K$560.00K$1.04M$1.22M$643.33K$965.00K$600.00K$395.00K$800.00K$990.00K$815.00K$1.26M$1.26M$1.26M$782.99K$1.25M
# Analysts11135422422211112222101010109999209
Surprise %--------2.87%2.60%0.51%2.36%6.11%1.13%0.41%0.31%0.32%0.13%5.41%0.71%6.31%1.69%0.29%2.76%1.09%0.43%0.57%1.13%4.16%0.98%

Celldex Therapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $809.00K, with a low forecast of $809.00K, and a high forecast of $809.00K. CLDX's average Quarter revenue forecast represents a -80.42% decrease compared to the company's last Quarter revenue of $4.13M (Dec 23).

Celldex Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11135422422211112222101010109999209
EBITDA--------$-32.17M$-38.26M$-30.50M$-35.58M$-29.28M$-27.94M$-18.70M$-23.73M$-20.25M$-17.02M$-12.23M$-15.00M$3.07M$-12.28M$-13.59M$-11.48M$-13.75M$-15.29M$-13.62M$-10.65M$72.90M$-27.57M
Avg Forecast$-650.00K$-433.33K$-433.33K$-433.33K$-1.02M$-835.56K$-854.29K$-17.71M$-1.44M$-583.33K$-528.00K$-18.95M$-17.68M$-360.00K$-400.00K$-20.26M$-1.04M$-1.22M$-14.50M$-965.00K$-600.00K$-395.00K$-800.00K$-11.14M$-815.00K$-1.26M$-1.26M$-12.26M$-228.53M$-33.28M
High Forecast$-650.00K$-433.33K$-433.33K$-433.33K$-655.91K$-835.56K$-854.14K$-14.17M$-1.07M$-583.17K$-528.00K$-15.16M$-14.14M$-360.00K$-400.00K$-16.21M$-1.04M$-1.22M$-11.60M$-965.00K$-600.00K$-395.00K$-800.00K$-8.91M$-815.00K$-1.26M$-1.26M$-9.81M$-182.83M$-26.63M
Low Forecast$-650.00K$-433.33K$-433.33K$-433.33K$-1.74M$-835.56K$-854.43K$-21.26M$-1.80M$-583.50K$-528.00K$-22.73M$-21.22M$-360.00K$-400.00K$-24.31M$-1.04M$-1.22M$-17.40M$-965.00K$-600.00K$-395.00K$-800.00K$-13.36M$-815.00K$-1.26M$-1.26M$-14.72M$-274.24M$-39.94M
Surprise %--------22.32%65.59%57.77%1.88%1.66%77.60%46.75%1.17%19.54%13.93%0.84%15.54%-5.11%31.08%16.98%1.03%16.87%12.14%10.81%0.87%-0.32%0.83%

2 analysts predict CLDX's average Quarter EBITDA for Mar 21 to be $-965.00K, with a high of $-965.00K and a low of $-965.00K. This is -131.45% lower than Celldex Therapeutics's previous annual EBITDA (Dec 20) of $3.07M.

Celldex Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11135422422211112222101010109999209
Net Income--------$-50.25M$-38.26M$-30.50M$-22.41M$-23.69M$-24.96M$-52.57M$-21.56M$-19.27M$-20.45M$-13.76M$-17.30M$-21.90M$-14.22M$-11.03M$-12.61M$-6.00M$-11.41M$-11.78M$-17.24M$-118.13M$-34.26M
Avg Forecast$-58.01M$-55.91M$-56.13M$-54.14M$-48.65M$-44.59M$-38.97M$-18.36M$-48.64M$-45.08M$-43.64M$-19.64M$-18.39M$-37.41M$-30.37M$-21.00M$-27.51M$-23.44M$-15.38M$-22.78M$-24.21M$-23.77M$-38.29M$-12.27M$-59.42M$-63.38M$-77.24M$-13.31M$-229.48M$-34.90M
High Forecast$-58.01M$-55.91M$-56.13M$-45.92M$-42.16M$-44.59M$-38.97M$-14.69M$-35.20M$-45.08M$-43.64M$-15.71M$-14.71M$-37.41M$-30.37M$-16.80M$-27.51M$-23.44M$-12.30M$-22.78M$-24.21M$-23.77M$-38.29M$-9.82M$-59.42M$-63.38M$-77.24M$-10.65M$-183.58M$-27.92M
Low Forecast$-58.01M$-55.91M$-56.13M$-62.36M$-56.43M$-44.59M$-38.97M$-22.03M$-58.24M$-45.08M$-43.64M$-23.56M$-22.07M$-37.41M$-30.37M$-25.20M$-27.51M$-23.44M$-18.45M$-22.78M$-24.21M$-23.77M$-38.29M$-14.72M$-59.42M$-63.38M$-77.24M$-15.97M$-275.38M$-41.88M
Surprise %--------1.03%0.85%0.70%1.14%1.29%0.67%1.73%1.03%0.70%0.87%0.89%0.76%0.90%0.60%0.29%1.03%0.10%0.18%0.15%1.30%0.51%0.98%

Celldex Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CLDX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Celldex Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11135422422211112222101010109999209
SG&A--------$8.83M$8.22M$7.22M$6.64M$6.60M$6.53M$7.15M$6.91M$6.24M$5.82M$4.31M$4.12M$3.62M$3.64M$3.53M$3.67M$3.22M$3.40M$3.91M$4.90M$5.59M$7.23M
Avg Forecast$3.47M$2.31M$2.31M$2.31M$5.43M$4.46M$4.56M$4.32M$7.70M$3.12M$2.82M$2.19M$1.41M$1.92M$2.14M$2.99M$5.53M$6.53M$3.44M$5.15M$3.20M$2.11M$4.27M$5.29M$4.35M$6.73M$6.73M$6.73M$5.23M$8.33M
High Forecast$3.47M$2.31M$2.31M$2.31M$9.28M$4.46M$4.56M$4.32M$9.62M$3.12M$2.82M$2.19M$1.41M$1.92M$2.14M$2.99M$5.53M$6.53M$3.44M$5.15M$3.20M$2.11M$4.27M$5.29M$4.35M$6.73M$6.73M$6.73M$6.27M$9.99M
Low Forecast$3.47M$2.31M$2.31M$2.31M$3.50M$4.46M$4.56M$4.32M$5.71M$3.11M$2.82M$2.19M$1.41M$1.92M$2.14M$2.99M$5.53M$6.53M$3.44M$5.15M$3.20M$2.11M$4.27M$5.29M$4.35M$6.73M$6.73M$6.73M$4.18M$6.66M
Surprise %--------1.15%2.64%2.56%3.03%4.68%3.40%3.35%2.31%1.13%0.89%1.25%0.80%1.13%1.73%0.83%0.69%0.74%0.51%0.58%0.73%1.07%0.87%

Celldex Therapeutics's average Quarter SG&A projection for Mar 24 is $4.32M, based on 2 Wall Street analysts, with a range of $4.32M to $4.32M. The forecast indicates a -51.09% fall compared to CLDX last annual SG&A of $8.83M (Dec 23).

Celldex Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18Mar 17
# Analysts11135422422211112222101010109999209
EPS--------$-1.04K$-0.81$-0.65$-0.47$-0.50$-0.53$-1.12$-0.46$-0.41$-0.45$-0.35$-0.44$-0.55$-0.39$-0.50$-0.72$-0.36$-0.41$-0.63$-1.83$-12.61$-4.81
Avg Forecast$-0.88$-0.84$-0.85$-0.82$-0.73$-0.67$-0.59$-0.69$-0.73$-0.68$-0.66$-0.62$-0.59$-0.57$-0.46$-0.45$-0.42$-0.35$-0.40$-0.34$-0.37$-0.36$-0.58$-0.71$-0.90$-0.96$-1.17$-1.14$-5.89$-4.36
High Forecast$-0.88$-0.84$-0.85$-0.69$-0.64$-0.67$-0.59$-0.69$-0.53$-0.68$-0.66$-0.62$-0.59$-0.57$-0.46$-0.45$-0.42$-0.35$-0.40$-0.34$-0.37$-0.36$-0.58$-0.71$-0.90$-0.96$-1.17$-1.14$-4.71$-3.49
Low Forecast$-0.88$-0.84$-0.85$-0.94$-0.85$-0.67$-0.59$-0.69$-0.88$-0.68$-0.66$-0.62$-0.59$-0.57$-0.46$-0.45$-0.42$-0.35$-0.40$-0.34$-0.37$-0.36$-0.58$-0.71$-0.90$-0.96$-1.17$-1.14$-7.06$-5.23
Surprise %--------1413.57%1.19%0.99%0.76%0.85%0.94%2.43%1.03%0.98%1.27%0.87%1.28%1.50%1.08%0.86%1.01%0.40%0.43%0.54%1.61%2.14%1.10%

According to undefined Wall Street analysts, Celldex Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CLDX previous annual EPS of $NaN (undefined).

Celldex Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
VTYXVentyx Biosciences$2.37$33.861328.69%Buy
ALXOALX Oncology$1.79$24.501268.72%Buy
KROSKeros Therapeutics$18.00$102.00466.67%Buy
AVTEAerovate Therapeutics$2.56$13.00407.81%Hold
BCABBioAtla$1.31$5.00281.68%Buy
ANABAnaptysBio$15.99$49.83211.63%Buy
IMTXImmatics$7.18$22.00206.41%Buy
CLDXCelldex Therapeutics$26.04$62.00138.10%Buy
IDYAIDEAYA Biosciences$26.33$53.33102.54%Buy
SWTXSpringWorks Therapeutics$37.72$76.00101.48%Buy
COGTCogent Biosciences$8.19$16.0095.36%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
CYTKCytokinetics$47.78$90.0088.36%Buy
DYNDyne Therapeutics$26.16$49.0087.31%Buy
RNAAvidity Biosciences$32.74$59.0080.21%Buy
EWTXEdgewise Therapeutics$30.17$46.2553.30%Buy
RVMDRevolution Medicines$45.16$65.6745.42%Buy
MGTXMeiraGTx$6.40$9.0040.63%Buy
TVTXTravere Therapeutics$17.14$21.7526.90%Buy
CRNXCrinetics Pharmaceuticals$55.37$69.0024.62%Buy

CLDX Forecast FAQ

Is Celldex Therapeutics a good buy?

Yes, according to 8 Wall Street analysts, Celldex Therapeutics (CLDX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 62.50% of CLDX's total ratings.

What is CLDX's price target?

Celldex Therapeutics (CLDX) average price target is $62 with a range of $44 to $80, implying a 146.62% from its last price of $25.14. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Celldex Therapeutics stock go up soon?

According to Wall Street analysts' prediction for CLDX stock, the company can go up by 146.62% (from the last price of $25.14 to the average price target of $62), up by 218.22% based on the highest stock price target, and up by 75.02% based on the lowest stock price target.

Can Celldex Therapeutics stock reach $40?

CLDX's average twelve months analyst stock price target of $62 supports the claim that Celldex Therapeutics can reach $40 in the near future.

What are Celldex Therapeutics's analysts' financial forecasts?

Celldex Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $3.52M (high $4.24M, low $3.15M), average EBITDA is $-20.42M (high $-16.517M, low $-24.685M), average net income is $-151M (high $-140M, low $-162M), average SG&A $18.77M (high $22.63M, low $16.85M), and average EPS is $-2.687 (high $-2.589, low $-2.804). CLDX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.95M (high $1.95M, low $1.95M), average EBITDA is $-1.95M (high $-1.95M, low $-1.95M), average net income is $-224M (high $-216M, low $-232M), average SG&A $10.41M (high $10.41M, low $10.41M), and average EPS is $-3.382 (high $-3.258, low $-3.506).

Did the CLDX's actual financial results beat the analysts' financial forecasts?

Based on Celldex Therapeutics's last annual report (Dec 2023), the company's revenue was $6.88M, beating the average analysts forecast of $2.96M by 132.32%. Apple's EBITDA was $-141M, beating the average prediction of $-21.498M by 557.87%. The company's net income was $-141M, missing the average estimation of $-157M by -9.92%. Apple's SG&A was $30.91M, beating the average forecast of $15.82M by 95.39%. Lastly, the company's EPS was $-2.919K, beating the average prediction of $-2.694 by 108253.50%. In terms of the last quarterly report (Dec 2023), Celldex Therapeutics's revenue was $4.13M, beating the average analysts' forecast of $1.44M by 186.59%. The company's EBITDA was $-32.171M, beating the average prediction of $-1.441M by 2131.88%. Celldex Therapeutics's net income was $-50.252M, beating the average estimation of $-48.643M by 3.31%. The company's SG&A was $8.83M, beating the average forecast of $7.7M by 14.74%. Lastly, the company's EPS was $-1.037K, beating the average prediction of $-0.734 by 141257.41%